TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

How TPR100 works

It contains 1.86% diclofenac and utilises our DermaSys® technology to achieve effective penetration for enhanced therapeutic benefits with fast, effective and long lasting relief.

DermaSys® enables a fast onset of relief at the site of pain and the potential for improved patient benefit by reducing the dosing frequency to twice daily.

Futura's unique DermaSys® technology enables targeted delivery of diclofenac through the skin to the site of action and sustained release.

Application of gel with diclofenac

Combination of solvents including volatile solvents

Seconds later

Volatile solvents evaporate, leaving the remaining solvent supersaturated with diclofenac.
The supersaturation powerfully drives diclofenac through the skin

Minutes later

Diclofenac penetrates the skin rapidly to reach the site of action.
Targeted delivery and sustained release

Compelling clinical data showing efficacy and safety profile

Early completed in vitro and in vivo studies showed significant superiority in terms of skin penetration of the diclofenac molecule for TPR100 compared with other commercially available products. These studies showed that TPR100 achieved up to 40 times higher bioavailability than those achieved by other commercially available products with none of the side effects which can be seen with oral non-steroidal anti-inflammatory drug (NSAID) products.

A randomised, double blind, crossover clinical proof of concept study in 20 healthy volunteers was conducted using a design in a model of induced pain. The skin of healthy volunteers was carefully exposed to a controlled amount of ultra-violet light to increase the sensitivity of the skin to pain stimuli. The effect of TPR100, Voltarol® gel and a placebo gel were assessed over a six hour time period post dosing using two criteria: the primary pain measurement was the volunteers' sensation of pain (heat pain tolerance test) and the secondary pain measurement was the level of inflammation (as indicated by erythema, reddening of the skin). The study data was encouraging, with TPR100 achieving efficacy against its clinical endpoints. The data provides a pathway for the product's further development and formed the basis of the submission for TPR100 for UK marketing approval by Thornton & Ross.

Improved permeation compared to market leaders at same dosage

TPR100 Human skin permeation study